Association Between Ceftriaxone Use and Biliary Infections in Patients With Pneumonia: A Nationwide Retrospective Cohort Study
Pharmacoepidemiology and Drug Safety · 2025
DOI: 10.1002/pds.70162 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Pharmacoepidemiology and Drug Safety, 2025. Verfasst von Jumpei Taniguchi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, Tokyo, Japan. Hauptthemen laut MEDLINE: Ceftriaxone, Anti-Bacterial Agents, Pneumonia, Cholangitis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Ministry of Health, Labor and Welfare, Japan.
Abstract (Originalsprache)
Background
Ceftriaxone is believed to increase the risk of biliary infections due to pseudolithiasis caused by ceftriaxone‐calcium precipitation, but this risk is not well understood. This study aimed to investigate whether ceftriaxone use is associated with an increased risk of biliary infections in pneumonia patients using a national inpatient database.
Methods
We analyzed the Diagnosis Procedure Combination database in Japan, identifying pneumonia patients between July 2010 and March 2022. Patients were grouped by treatment: ceftriaxone versus ampicillin‐sulbactam or cefotaxime. Propensity score overlap‐weighting was used to adjust for confounding factors. The primary outcome was a composite measure, including cholecystitis or cholangitis during hospitalization, and any percutaneous, endoscopic, or surgical interventions on the biliary tract. Secondary outcomes included individual components of the primary outcome.
Results
Of the 1 503 885 eligible patients, 558 725 received ceftriaxone, while 945 160 were treated with either ampicillin‐sulbactam or cefotaxime. The mean dose of ceftriaxone was 1.7 g/day (standard deviation, 0.7 g/day), with a mean administration duration of 7.1 days (standard deviation, 3.8 days). Propensity score overlap‐weighting analysis revealed that ceftriaxone treatment was associated with an increased incidence of the composite outcome (0.22% vs. 0.18%; risk difference, 0.05%; 95% confidence interval, 0.03%–0.07%; p < 0.001), as well as the secondary outcomes, including cholecystitis or cholangitis during hospitalization and percutaneous or endoscopic drainage of the gallbladder or biliary tract.
Conclusion
Ceftriaxone use was associated with a slight increase in the risk of biliary infections.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, Tokyo, Japan.
- Department of Health Services Research, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
- Department of Health Policy and Informatics, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, Tokyo, Japan.
ORCID-Profile: Jumpei Taniguchi, Shotaro Aso, Hideo Yasunaga
Förderung
- The Ministry of Health, Labor and Welfare, Japan
Zitieren
APA
Taniguchi, J., Aso, S., Matsui, H., Fushimi, K., & Yasunaga, H. (2025). Association Between Ceftriaxone Use and Biliary Infections in Patients With Pneumonia: A Nationwide Retrospective Cohort Study. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.70162
Vancouver
Taniguchi J, Aso S, Matsui H, Fushimi K, Yasunaga H. Association Between Ceftriaxone Use and Biliary Infections in Patients With Pneumonia: A Nationwide Retrospective Cohort Study. Pharmacoepidemiology and Drug Safety. 2025. doi:10.1002/pds.70162
BibTeX
@article{Taniguchi2025,
author = {Taniguchi, Jumpei and Aso, Shotaro and Matsui, Hiroki and Fushimi, Kiyohide and Yasunaga, Hideo},
title = {Association Between Ceftriaxone Use and Biliary Infections in Patients With Pneumonia: A Nationwide Retrospective Cohort Study},
journal = {Pharmacoepidemiology and Drug Safety},
year = {2025},
doi = {10.1002/pds.70162}
}
EUVIMED